I had a look at the press release for P-II/III results on Sensamide used to treat non-small cell lung cancer. (Neu-Sensamide is supposed to be a formulation with fewer side affects than Sensamide.) In the study they found a sub-population that appears to benefit from addition of Sensamide to normal radiation treatment. This sub-population may be a small part of the total. I found a definition of Karnofssky Performance Scale and list the first part after the press release excerpt.
Jason
--------------------
Boston, MA and Lund, Sweden, March 31, 1998 - OXiGENE (Nasdaq: OXGN, SSE: OXGN), an international biopharmaceutical company, reported today on developments in its clinical trials with Neu-Sensamide™, a radiosensitizer, and Sensamide™, a prototype for Neu-Sensamide.
Clinical investigators have now completed the collection and evaluation of tumor response data for the Company's randomized, controlled Phase II/III study of the prototype Sensamide in patients with non-small cell lung cancer (NSCLC). Based on this analysis, OXiGENE has identified a patient sub-group for whom Sensamide, and the Company's lead product, Neu-Sensamide, are expected to have efficacy. The study shows that more patients with squamous cell carcinoma, the most common form of lung cancer, and a Karnofsky score** >= 90 who were treated with radiation and Sensamide experienced tumor response (
47%), compared to patients receiving radiation alone (30%), and randomized to the same sub-group...
-------------------
Complete PR is at oxigene.com
-------------------
Karnofsky Performance Scale
100 Normal, no complaints, no evidence of disease
90 Able to carry on normal activity: minor symptoms of disease
80 Normal activity with effort: some symptoms of disease
70 Cares for self: unable to carry on normal activity or active work
60 Requires occasional assistance but is able to care for needs
Complete definition at catalog.com |
